Patents by Inventor Harry E. Gruber

Harry E. Gruber has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RETROVIRAL VECTOR HAVING IMMUNE-STIMULATING ACTIVITY
    Publication number: 20220195460
    Abstract: The disclosure provides vectors for treating cancers, method of producing such vectors and methods of use of the vectors.
    Type: Application
    Filed: December 16, 2021
    Publication date: June 23, 2022
    Applicant: DENOVO BIOPHARMA LLC
    Inventors: Harry E. GRUBER, Douglas J. JOLLY, Amy H. LIN, Joan M, ROBBINS, Derek G. OSTERTAG
  • Retroviral vector having immune-stimulating activity
    Patent number: 11230719
    Abstract: The disclosure provides vectors for treating cancers, method of producing such vectors and methods of use of the vectors.
    Type: Grant
    Filed: March 25, 2015
    Date of Patent: January 25, 2022
    Assignee: DENOVO BIOPHARMA LLC
    Inventors: Harry E. Gruber, Douglas J. Jolly, Amy H. Lin, Joan M. Robbins, Derek G. Ostertag
  • Formulations of 5-fluorocytosine and uses thereof
    Patent number: 11191764
    Abstract: The disclosure provides an extended release formulation of 5-fluorocytosine. In another aspect, a method of treating a fungal disease is provided. The method comprises administering to a subject in need thereof a fungus-treating effective amount of a composition comprising 5-fluorocytosine. In yet another aspect, a method of treating a cancer is provided. The method comprises administering to a subject in need thereof a sufficient amount of an expression vector to induce expression of cytosine deaminase which is capable of converting 5-fluorocytosine to 5-fluorourcail in cells of the cancer and a cancer-treating effective amount of a composition comprising 5-fluorocytosine.
    Type: Grant
    Filed: October 16, 2019
    Date of Patent: December 7, 2021
    Assignee: DENOVO BIOPHARMA LLC
    Inventors: Harry E. Gruber, Douglas J. Jolly, Kay Olmstead
  • ENHANCED CANCER TREATMENT AND MONITORING USING RECOMBINANT VECTORS
    Publication number: 20210361691
    Abstract: This disclosure relates to replication competent viral vectors for treating cell proliferative disorders. The disclosure further relates to the use of such replication competent viral vectors for delivery and expression of a heterologous nucleic acid in normal and diseased tissues and methods and compositions that facilitate such delivery and expression to tissues in vivo and in vitro. The disclosure further relates to replication competent retroviral vectors for these uses and in conjunction with methods and compositions that facilitate in vivo therapeutics.
    Type: Application
    Filed: March 1, 2021
    Publication date: November 25, 2021
    Applicant: DENOVO BIOPHARMA, LLC
    Inventors: Harry E. Gruber, Douglas J. Jolly, Derek G. Ostertag, Ryan S. Burnett, Amy H. Lin, Tiffany Huang, Joan M. Robbins
  • Retroviral vector with mini-promoter cassette
    Patent number: 11065311
    Abstract: This disclosure provides a retroviral replicating vector for gene delivery comprising a therapeutic cassette containing at least one mini-promoter linked to a gene to be expressed.
    Type: Grant
    Filed: October 24, 2013
    Date of Patent: July 20, 2021
    Assignee: DENOVO BIOPHARMA LLC
    Inventors: Harry E. Gruber, Douglas J. Jolly, Amy H. Lin, Christopher R. Logg, Noriyuki Kasahara
  • FORMULATIONS OF 5-FLUOROCYTOSINE AND USES THEREOF
    Publication number: 20200281929
    Abstract: The disclosure provides an extended release formulation of 5-fluorocytosine. In another aspect, a method of treating a fungal disease is provided. The method comprises administering to a subject in need thereof a fungus-treating effective amount of a composition comprising 5-fluorocytosine. In yet another aspect, a method of treating a cancer is provided. The method comprises administering to a subject in need thereof a sufficient amount of an expression vector to induce expression of cytosine deaminase which is capable of converting 5-fluorocytosine to 5-fluorourcail in cells of the cancer and a cancer-treating effective amount of a composition comprising 5-fluorocytosine.
    Type: Application
    Filed: October 16, 2019
    Publication date: September 10, 2020
    Applicant: Tocagen Inc.
    Inventors: Harry E. Gruber, Douglas J. Jolly, Kay Olmstead
  • RECOMBINANT VECTORS
    Publication number: 20200239858
    Abstract: This disclosure provides modified cytosine deaminases (CDs). The disclosure further relates to cells and vector expressing or comprising such modified CDs and methods of using such modified CDs in the treatment of disease and disorders.
    Type: Application
    Filed: September 4, 2019
    Publication date: July 30, 2020
    Inventors: Harry E. Gruber, Douglas J. Jolly, Omar D. Perez, Christopher R. Logg
  • Formulations of 5-fluorocytosine and uses thereof
    Patent number: 10449194
    Abstract: The disclosure provides an extended release formulation of 5-fluorocytosine. In another aspect, a method of treating a fungal disease is provided. The method comprises administering to a subject in need thereof a fungus-treating effective amount of a composition comprising 5-fluorocytosine. In yet another aspect, a method of treating a cancer is provided. The method comprises administering to a subject in need thereof a sufficient amount of an expression vector to induce expression of cytosine deaminase which is capable of converting 5-fluorocytosine to 5-fluorouracil in cells of the cancer and a cancer-treating effective amount of a composition comprising 5-fluorocytosine.
    Type: Grant
    Filed: February 7, 2018
    Date of Patent: October 22, 2019
    Assignee: Tocagen Inc.
    Inventors: Harry E. Gruber, Douglas J. Jolly, Kay Olmstead
  • Recombinant vectors
    Patent number: 10407666
    Abstract: This disclosure provides modified cytosine deaminases (CDs). The disclosure further relates to cells and vector expressing or comprising such modified CDs and methods of using such modified CDs in the treatment of disease and disorders.
    Type: Grant
    Filed: August 8, 2017
    Date of Patent: September 10, 2019
    Assignee: Tocagen Inc.
    Inventors: Harry E. Gruber, Douglas J. Jolly, Omar D. Perez, Christopher R. Logg
  • GENE THERAPY VECTORS AND CYTOSINE DEAMINASES
    Publication number: 20190185821
    Abstract: This disclosure provides modified cytosine deaminases(CDs). The disclosure further relates to cells and vector expressing or comprising such modified CDs and methods of using such modified CDs in the treatment of disease and disorders.
    Type: Application
    Filed: July 24, 2018
    Publication date: June 20, 2019
    Applicant: Tocagen Inc.
    Inventors: Harry E. Gruber, Douglas J. Jolly, Omar D. Perez, Christopher R. Logg
  • FORMULATIONS OF 5-FLUOROCYTOSINE AND USES THEREOF
    Publication number: 20190015414
    Abstract: The disclosure provides an extended release formulation of 5-fluorocytosine. In another aspect, a method of treating a fungal disease is provided. The method comprises administering to a subject in need thereof a fungus-treating effective amount of a composition comprising 5-fluorocytosine. In yet another aspect, a method of treating a cancer is provided. The method comprises administering to a subject in need thereof a sufficient amount of an expression vector to induce expression of cytosine deaminase which is capable of converting 5-fluorocytosine to 5-fluorouracil in cells of the cancer and a cancer-treating effective amount of a composition comprising 5-fluorocytosine.
    Type: Application
    Filed: February 7, 2018
    Publication date: January 17, 2019
    Inventors: Harry E. Gruber, Douglas J. Jolly, Kay Olmstead
  • Gene therapy vectors and cytosine deaminases
    Patent number: 10035983
    Abstract: This disclosure provides modified cytosine deaminases (CDs). The disclosure further relates to cells and vector expressing or comprising such modified CDs and methods of using such modified CDs in the treatment of disease and disorders.
    Type: Grant
    Filed: May 9, 2014
    Date of Patent: July 31, 2018
    Assignee: Tocagen Inc.
    Inventors: Harry E. Gruber, Douglas J. Jolly, Omar D. Perez, Christopher R. Logg
  • RECOMBINANT VECTORS
    Publication number: 20180087035
    Abstract: This disclosure provides modified cytosine deaminases (CDs). The disclosure further relates to cells and vector expressing or comprising such modified CDs and methods of using such modified CDs in the treatment of disease and disorders.
    Type: Application
    Filed: August 8, 2017
    Publication date: March 29, 2018
    Inventors: Harry E. Gruber, Douglas J. Jolly, Omar D. Perez, Christopher R. Logg
  • Formulations of 5-fluorocytosine and uses thereof
    Patent number: 9889133
    Abstract: The disclosure provides an extended release formulation of 5-fluorocytosine. In another aspect, a method of treating a fungal disease is provided. The method comprises administering to a subject in need thereof a fungus-treating effective amount of a composition comprising 5-fluorocytosine. In yet another aspect, a method of treating a cancer is provided. The method comprises administering to a subject in need thereof a sufficient amount of an expression vector to induce expression of cytosine deaminase which is capable of converting 5-fluorocytosine to 5-fluorourcail in cells of the cancer and a cancer-treating effective amount of a composition comprising 5-fluorocytosine.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: February 13, 2018
    Assignee: Tocagen Inc.
    Inventors: Harry E. Gruber, Douglas J. Jolly, Kay Olmstead
  • ENHANCED CANCER TREATMENT AND MONITORING USING RECOMBINANT VECTORS
    Publication number: 20180021365
    Abstract: This disclosure relates to replication competent viral vectors for treating cell proliferative disorders. The disclosure further relates to the use of such replication competent viral vectors for delivery and expression of a heterologous nucleic acid in normal and diseased tissues and methods and compositions that facilitate such delivery and expression to tissues in vivo and in vitro. The disclosure further relates to replication competent retroviral vectors for these uses and in conjunction with methods and compositions that facilitate in vivo therapeutics.
    Type: Application
    Filed: June 1, 2017
    Publication date: January 25, 2018
    Inventors: Harry E. Gruber, Douglas J. Jolly, Derek G. Ostertag, Ryan S. Burnett, Amy H. Lin, Tiffany Huang, Joan M. Robbins
  • Recombinant vectors
    Patent number: 9732326
    Abstract: This disclosure provides modified cytosine deaminases (CDs). The disclosure further relates to cells and vector expressing or comprising such modified CDs and methods of using such modified CDs in the treatment of disease and disorders.
    Type: Grant
    Filed: September 4, 2014
    Date of Patent: August 15, 2017
    Assignee: Tocagen Inc.
    Inventors: Harry E. Gruber, Douglas J. Jolly, Omar D. Perez, Christopher R. Logg
  • RETROVIRAL VECTOR HAVING IMMUNE-STIMULATING ACTIVITY
    Publication number: 20170175137
    Abstract: The disclosure provides vectors for treating cancers, method of producing such vectors and methods of use of the vectors.
    Type: Application
    Filed: March 25, 2015
    Publication date: June 22, 2017
    Inventors: Harry E. Gruber, Douglas J. Jolly, Amy H. Lin, Joan M. Robbins, Derek G. Ostertag
  • Compositions comprising gamma retrovirus vectors and methods of treating proliferative disorders
    Patent number: 9669049
    Abstract: This disclosure relates to replication competent viral vectors for treating cell proliferative disorders. The disclosure further relates to the use of such replication competent viral vectors for delivery and expression of a heterologous nucleic acid in normal and diseased tissues and methods and compositions that facilitate such delivery and expression to tissues in vivo and in vitro. The disclosure further relates to replication competent retroviral vectors for these uses and in conjunction with methods and compositions that facilitate in vivo therapeutics.
    Type: Grant
    Filed: October 31, 2011
    Date of Patent: June 6, 2017
    Assignee: Tocagen Inc.
    Inventors: Harry E. Gruber, Douglas J. Jolly, Derek G. Ostertag, Ryan S. Burnett, Amy H. Lin, Tiffany Huang, Joan M. Robbins
  • Cancer combination therapy and recombinant vectors
    Patent number: 9642921
    Abstract: This disclosure relates to a combination therapy of chemotherapeutics and/or radiosensitizing agents with a replication competent viral vectors for treating cell proliferative disorders and chemotherapeutic treatments. The disclosure further relates to the use of such replication competent viral vectors for delivery and expression of a heterologous nucleic acid in normal and diseased tissues and methods and compositions that facilitate such delivery and expression to tissues in vivo and in vitro. The disclosure further relates to replication competent retroviral vectors for these uses and in conjunction with methods and compositions that facilitate in vivo therapeutics.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: May 9, 2017
    Assignee: Tocagen Inc.
    Inventors: Joan M. Robbins, Douglas J. Jolly, Derek G. Ostertag, Tiffany Huang, Harry E. Gruber
  • FORMULATIONS OF 5-FLUOROCYTOSINE AND USES THEREOF
    Publication number: 20160235751
    Abstract: The disclosure provides an extended release formulation of 5-fluorocytosine. In another aspect, a method of treating a fungal disease is provided. The method comprises administering to a subject in need thereof a fungus-treating effective amount of a composition comprising 5-fluorocytosine. In yet another aspect, a method of treating a cancer is provided. The method comprises administering to a subject in need thereof a sufficient amount of an expression vector to induce expression of cytosine deaminase which is capable of converting 5-fluorocytosine to 5-fluorourcail in cells of the cancer and a cancer-treating effective amount of a composition comprising 5-fluorocytosine.
    Type: Application
    Filed: April 22, 2016
    Publication date: August 18, 2016
    Inventors: Harry E. Gruber, Douglas J. Jolly, Kay Olmstead